tetano
Editor, Senior Moderator
Viruses
. 2022 Sep 12;14(9):2017.
doi: 10.3390/v14092017.
Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics
Andrei Veleanu[SUP] 1 [/SUP], Maximilian A Kelch[SUP] 1 [/SUP], Chengjin Ye[SUP] 2 [/SUP], Melanie Flohr[SUP] 1 [/SUP], Alexander Wilhelm[SUP] 1 [/SUP], Marek Widera[SUP] 1 [/SUP], Luis Martinez-Sobrido[SUP] 2 [/SUP], Sandra Ciesek[SUP] 1 3 4 [/SUP], Tuna Toptan[SUP] 1 [/SUP]
Affiliations
Abstract
Some of the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are less susceptible to neutralization with post-vaccine sera and monoclonal antibodies targeting the viral spike glycoprotein. This raises concerns of disease control, transmissibility, and severity. Numerous substitutions have been identified to increase viral fitness within the nucleocapsid and nonstructural proteins, in addition to spike mutations. Therefore, we sought to generate infectious viruses carrying only the variant-specific spike mutations in an identical backbone to evaluate the impact of spike and non-spike mutations in the virus life cycle. We used en passant mutagenesis to generate recombinant viruses carrying spike mutations of B.1 and B.1.617.2 variants using SARS-CoV-2- bacterial artificial chromosome (BAC). Neutralization assays using clinical sera yielded comparable results between recombinant viruses and corresponding clinical isolates. Non-spike mutations for both variants neither seemed to effect neutralization efficiencies with monoclonal antibodies nor the response to treatment with inhibitors. However, live-cell imaging and microscopy revealed differences, such as persisting syncytia and pronounced cytopathic effect formation, as well as their progression between BAC-derived viruses and clinical isolates in human lung epithelial cell lines and primary bronchial epithelial cells. Complementary RNA analyses further suggested a potential role of non-spike mutations in infection kinetics.
Keywords: BAC mutagenesis; SARS-CoV-2; VoC; en passant mutagenesis; spike protein.
. 2022 Sep 12;14(9):2017.
doi: 10.3390/v14092017.
Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics
Andrei Veleanu[SUP] 1 [/SUP], Maximilian A Kelch[SUP] 1 [/SUP], Chengjin Ye[SUP] 2 [/SUP], Melanie Flohr[SUP] 1 [/SUP], Alexander Wilhelm[SUP] 1 [/SUP], Marek Widera[SUP] 1 [/SUP], Luis Martinez-Sobrido[SUP] 2 [/SUP], Sandra Ciesek[SUP] 1 3 4 [/SUP], Tuna Toptan[SUP] 1 [/SUP]
Affiliations
- PMID: 36146823
- DOI: 10.3390/v14092017
Abstract
Some of the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are less susceptible to neutralization with post-vaccine sera and monoclonal antibodies targeting the viral spike glycoprotein. This raises concerns of disease control, transmissibility, and severity. Numerous substitutions have been identified to increase viral fitness within the nucleocapsid and nonstructural proteins, in addition to spike mutations. Therefore, we sought to generate infectious viruses carrying only the variant-specific spike mutations in an identical backbone to evaluate the impact of spike and non-spike mutations in the virus life cycle. We used en passant mutagenesis to generate recombinant viruses carrying spike mutations of B.1 and B.1.617.2 variants using SARS-CoV-2- bacterial artificial chromosome (BAC). Neutralization assays using clinical sera yielded comparable results between recombinant viruses and corresponding clinical isolates. Non-spike mutations for both variants neither seemed to effect neutralization efficiencies with monoclonal antibodies nor the response to treatment with inhibitors. However, live-cell imaging and microscopy revealed differences, such as persisting syncytia and pronounced cytopathic effect formation, as well as their progression between BAC-derived viruses and clinical isolates in human lung epithelial cell lines and primary bronchial epithelial cells. Complementary RNA analyses further suggested a potential role of non-spike mutations in infection kinetics.
Keywords: BAC mutagenesis; SARS-CoV-2; VoC; en passant mutagenesis; spike protein.